Inhibition of calcium-activated potassium conductance of human erythrocytes by calmodulin inhibitory drugs.
D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors; D017301:Ca(2+) Mg(2+)-ATPase; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000494:pharmacology*; D002135:Calcium-Binding Proteins / Q000037:antagonists & inhibitors*; D000252:Calcium-Transporting ATPases / Q000037:antagonists & inhibitors; D002147:Calmodulin / Q000037:antagonists & inhibitors*; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000378:metabolism*; D004912:Erythrocytes / Q000378:metabolism*; D005484:Fluspirilene / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D010395:Penfluridol / Q000494:pharmacology; D010640:Phenothiazines / Q000494:pharmacology; D010868:Pimozide / Q000494:pharmacology; D011188:Potassium / Q000097:blood*
D002135:Calcium-Binding Proteins; D002147:Calmodulin; D010640:Phenothiazines; D010868:Pimozide; D010395:Penfluridol; D000001:Calcimycin; D005484:Fluspirilene; D000251:Adenosine Triphosphatases; D017301:Ca(2+) Mg(2+)-ATPase; D000252:Calcium-Transporting ATPases; D011188:Potassium; D002118:Calcium